Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This study will use the drug daratumumab in patients who did not achieve at least a very good
partial response (VGPR) and are already planned to have an Autologous Stem Cell Transplant
(ASCT). Daratumumab will be given before the stem cell collection to attempt to get rid of
any multiple myeloma cells that may be present in the stem cell collection and after the ASCT
to get rid of any multiple myeloma cells that may be remaining.